Literature DB >> 29103816

All grades of severity of postoperative adverse events are associated with prolonged length of stay after lung cancer resection.

Zach Zhang1, Fargol Mostofian1, Jelena Ivanovic2, Sebastien Gilbert3, Donna E Maziak4, Farid M Shamji5, Sudhir Sundaresan3, Patrick J Villeneuve5, Andrew J E Seely6.   

Abstract

OBJECTIVE: To determine whether all grades of severity of postoperative adverse events are associated with prolonged length of stay in patients undergoing pulmonary cancer resection.
METHODS: This was a retrospective cohort study of all patients who underwent pulmonary resection with curative intent for malignancy at The Ottawa Hospital, Division of Thoracic Surgery (January 2008 to July 2015). Postoperative adverse events were collected prospectively with the Thoracic Morbidity & Mortality System, based on the Clavien-Dindo severity classification. Patient demographics, comorbidities, preoperative investigations, cardiopulmonary assessment, pathologic staging, operative characteristics, and length of stay were retrospectively reviewed. Prolonged hospital stay was defined as >75th percentile for each procedure performed (wedge resection 6 days, segmentectomy 6 days, lobectomy 7 days, extended lobectomy 8 days, pneumonectomy 10 days). Univariable and multivariable logistic regression analyses were conducted to identify factors associated with prolonged hospital stay.
RESULTS: Of 1041 patients, 579 (55.6%) were female, 610 (58.1%) were >65 years old, 232 (22.3%) experienced prolonged hospital stay, and 416 (40.0%) patients had ≥1 postoperative adverse event. Multivariable analyses identified significant (P < .05) factors associated with prolonged hospital stay to be (odds ratio; 95% confidence interval): lower diffusion capacity of the lung for carbon monoxide (0.99; 0.98-0.99), surgical approach: open thoracotomy (1.8; 1.3-2.5), and presence of any postoperative adverse event: Grade I (5.8; 3.3-10.2), Grade II (6.0; 4.0-8.9), Grade III (11.4; 7.0-18.7), and Grade IV (19.40; 7.1-55.18).
CONCLUSIONS: Lower diffusion capacity of the lung for carbon monoxide, open thoracotomy approach, and the development of any postoperative adverse event, including minor events that required no additional therapy, were factors associated with prolonged hospital stay.
Copyright © 2017 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lung cancer; perioperative risk factors; postoperative adverse events; prolonged length of stay; pulmonary resection

Mesh:

Year:  2017        PMID: 29103816     DOI: 10.1016/j.jtcvs.2017.09.094

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

Review 1.  Interventions to avoid pulmonary complications after lung cancer resection.

Authors:  Patrick James Villeneuve
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

2.  Long-term impact of complications after lung resections in non-small cell lung cancer.

Authors:  Shuichi Shinohara; Kenichi Kobayashi; Chinatsu Kasahara; Takamitsu Onitsuka; Masaki Matsuo; Makoto Nakagawa; Masakazu Sugaya
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

3.  A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors After Curative-Intent Treatment.

Authors:  Duc Ha; Jacqueline Kerr; Andrew L Ries; Mark M Fuster; Scott M Lippman; James D Murphy
Journal:  Am J Phys Med Rehabil       Date:  2020-03       Impact factor: 3.412

4.  Risk factors for postoperative pneumonia and prognosis in lung cancer patients after surgery: A retrospective study.

Authors:  Lijun Yao; Jun Luo; Lu Liu; Qingchen Wu; Ruiqin Zhou; Linjun Li; Cheng Zhang
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

5.  Sugammadex is associated with shorter hospital length of stay after open lobectomy for lung cancer: a retrospective observational study.

Authors:  Seung Won Song; Kyung Yeon Yoo; Yong Sung Ro; Taehee Pyeon; Hong-Beom Bae; Joungmin Kim
Journal:  J Cardiothorac Surg       Date:  2021-03-23       Impact factor: 1.637

Review 6.  Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC.

Authors:  John F Roller; Nirmal K Veeramachaneni; Jun Zhang
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

7.  The Effect of Major and Minor Complications After Lung Surgery on Length of Stay and Readmission.

Authors:  Christian J Finley; Housne A Begum; Kendra Pearce; John Agzarian; Waël C Hanna; Yaron Shargall; Noori Akhtar-Danesh
Journal:  J Patient Exp       Date:  2022-02-01

8.  Meta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer.

Authors:  Christopher Cao; Anthony Le; Matthew Bott; Chi-Fu Jeffrey Yang; Dominique Gossot; Franca Melfi; David H Tian; Allen Guo
Journal:  Curr Oncol       Date:  2021-11-14       Impact factor: 3.109

9.  Prediction of Prolonged Length of Stay for Stroke Patients on Admission for Inpatient Rehabilitation Based on the International Classification of Functioning, Disability, and Health (ICF) Generic Set: A Study from 50 Centers in China.

Authors:  Xia Zhang; Huaide Qiu; Shouguo Liu; Jianan Li; Mouwang Zhou
Journal:  Med Sci Monit       Date:  2020-01-05

10.  Measuring adverse events following hip arthroplasty surgery using administrative data without relying on ICD-codes.

Authors:  Martin Magnéli; Maria Unbeck; Cecilia Rogmark; Olof Sköldenberg; Max Gordon
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.